| Literature DB >> 24507769 |
Anjali Patwardhan1, Michael Henrickson, Laura Laskosz, Sandy Duyenhong, Charles H Spencer.
Abstract
BACKGROUND: Pediatric Rheumatology (PR) training in the US has existed since the 1970's. In the early 1990's, the training was formalized into a three year training program by the American College of Graduate Medical Education (ACGME) and American Board of Pediatrics (ABP). Programs have been evaluated every 5 years by the ACGME to remain credentialed and graduates had to pass a written exam to be certified. There has been no report yet that details not just what training fellows should receive in the 32 US PR training programs but what training the trainees are actually receiving.Entities:
Mesh:
Year: 2014 PMID: 24507769 PMCID: PMC3922187 DOI: 10.1186/1546-0096-12-8
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Years after graduation from medical school of rheumatology fellows surveyed
| Years | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| # Fellows | 2 | 2 | 6 | 14 | 8 | 3 | 2 | 3 |
| % Fellows | 5 | 5 | 15 | 35 | 20 | 7.5 | 5 | 7.5 |
Total respondents = 40.
Extent of exposure of more common pediatric rheumatic diseases during entire fellowship
| | |||||
|---|---|---|---|---|---|
| Systemic JIA | Percentage of fellows who saw the patients in each group of column -B with diseases listed in column –A | 16% | 47% | 28% | 9% |
| Poly JIA | 4% | 7% | 14% | 75% | |
| Oligo JIA | 4% | 0% | 15% | 81% | |
| Enthesitis-related JIA | 7% | 16% | 25% | 52% | |
| SLE-New case | 30% | 34% | 32% | 4% | |
| SLE-existing diagnosis | 11% | 14% | 32% | 43% | |
| SLE with nephritis | 21% | 25% | 27% | 27% | |
| JDM-new case | 57% | 30% | 4% | 9% | |
| JDM-existing diagnosis | 31% | 30% | 25% | 14% | |
| Scleroderma | 47% | 29% | 20% | 4% | |
| Streptococcal syndromes | 20% | 39% | 37% | 4% | |
| Resistant HSP | 54% | 30% | 9% | 7% | |
| Kawasaki Disease | 21% | 46% | 19% | 14% | |
| Sarcoidosis | 61% | 34% | 5% | 0% | |
| Pain syndromes | 2% | 16% | 18% | 64% | |
(44 responded).
Abbreviations: JIA juvenile idiopathic arthritis, SLE systemic lupus erythematosus, JDM juvenile dermatomyositis, Streptococcal syndromes include rheumatic fever, post-streptococcal reactive arthritis and PANDA (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections), HSP Henoch Schӧenlein purpura.
Extent of exposure to joint injections during fellowship years of each fellow
| TMJ | 100 | 0 | 0 | 0 |
| Shoulders | 92 | 6 | 0 | 2 |
| Elbows | 71 | 26 | 3 | 0 |
| Wrists | 52 | 34 | 7 | 7 |
| MCPs | 82 | 5 | 5 | 8 |
| PIPs | 74 | 11 | 11 | 4 |
| IP’s | 77 | 18 | 2 | 3 |
| Hips | 100 | 0 | 0 | 0 |
| Knees | 7 | 7 | 26 | 60 |
| Ankles | 44 | 37 | 7 | 12 |
Total respondents = 44.
Note: The experience is quantitated by dividing the experience in different subgroups based on “Number Joints injected”. The numbers in italics in each subgroup denote% of responders in each subgroup.
Extent of disease exposure of less common pediatric rheumatic diseases and musculoskeletal syndromes during entire fellowship
| | |||||
|---|---|---|---|---|---|
| Sjogren’s syndrome | Percentage of fellows who saw the patients in each group of column -B with diseases listed in column –A | 72% | 23% | 5% | 0% |
| New WG (GPA) | 93% | 7% | 0% | 0% | |
| Existing WG Diagnosis | 73% | 22% | 5% | 0% | |
| PAN | 98% | 2% | 0% | 0% | |
| MPA | 93% | 7% | 0% | 0% | |
| CNS vasculitis | 82% | 18% | 0% | 0% | |
| Behcet’s syndrome | 84% | 14% | 2% | 0% | |
| Churg-Strauss syndrome | 100% | 0% | 0% | 0% | |
| Other ANCA-related syndromes | 84% | 8% | 8% | 0% | |
| APLS | 69% | 21% | 8% | 2% | |
| Periodic Fever syndromes | 85% | 14% | 1% | 0% | |
| CRMO | 72% | 26% | 2% | 0% | |
| MAS | 91% | 7% | 2% | 0% | |
(44 responded).
Abbreviations: WG Wegener’s Granulomatosis (GPA granulomatosis with polyangiitis), PAN polyarteritis nodosa, MPA microscopic polyangiitis, CNS central nervous system, ANCA anti-neutrophilic cytoplasmic antibody, APLS antiphospholipid syndrome, CRMO chronic recurrent multicentric osteomyelitis, MAS macrophage activation syndrome.